{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:13Z","timestamp":1792182313323,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1124\/mol.113.089755","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T05:09:20Z","timestamp":1381295360000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice"],"prefix":"10.1016","volume":"85","author":[{"given":"Lindsay B.","family":"Avery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namandj\u00e9 N.","family":"Bumpus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.113.089755_bib1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bms.1200101103","article-title":"Identification of valproic acid metabolites in human serum and urine using hexadeuterated valproic acid and gas chromatographic mass spectrometric analysis","volume":"10","author":"Acheampong","year":"1983","journal-title":"Biomed Mass Spectrom"},{"key":"10.1124\/mol.113.089755_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0003-9861(83)90602-1","article-title":"Influence of valproic acid on hepatic carbohydrate and lipid metabolism","volume":"223","author":"Becker","year":"1983","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/mol.113.089755_bib3","series-title":"Biochemistry, 5th ed","author":"Berg","year":"2002"},{"key":"10.1124\/mol.113.089755_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","article-title":"Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects","volume":"25","author":"Bonnefont","year":"2004","journal-title":"Mol Aspects Med"},{"key":"10.1124\/mol.113.089755_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.taap.2011.09.008","article-title":"Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes","volume":"257","author":"Bumpus","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/mol.113.089755_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0006-2952(90)90560-8","article-title":"Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid","volume":"40","author":"Cotariu","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.113.089755_bib7","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2337\/db06-0885","article-title":"The leptin-deficient (ob\/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity","volume":"55","author":"Drel","year":"2006","journal-title":"Diabetes"},{"key":"10.1124\/mol.113.089755_bib8","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.113.089755_bib9","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/db13-0368","article-title":"AMPK: a target for drugs and natural products with effects on both diabetes and cancer","volume":"62","author":"Hardie","year":"2013","journal-title":"Diabetes"},{"key":"10.1124\/mol.113.089755_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.110.175851","article-title":"Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway","volume":"337","author":"Hsu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.113.089755_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn","year":"2005","journal-title":"Cell Metab"},{"key":"10.1124\/mol.113.089755_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.4088\/JCP.v64n1205","article-title":"Bipolar disorder, obesity, and pharmacotherapy-associated weight gain","volume":"64","author":"Keck","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/mol.113.089755_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0968-0004(98)01340-1","article-title":"Dealing with energy demand: the AMP-activated protein kinase","volume":"24","author":"Kemp","year":"1999","journal-title":"Trends Biochem Sci"},{"key":"10.1124\/mol.113.089755_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.taap.2011.03.004","article-title":"Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicity","volume":"252","author":"Kiang","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/mol.113.089755_bib15","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/AAC.01401-13","article-title":"Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison","volume":"57","author":"Lade","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.089755_bib16","doi-asserted-by":"crossref","first-page":"9263","DOI":"10.1073\/pnas.0403108101","article-title":"The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and \u03b2 2-microglobulin-deficient hepatocytes","volume":"101","author":"Lee","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.089755_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature10804","article-title":"Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK","volume":"482","author":"Lin","year":"2012","journal-title":"Nature"},{"key":"10.1124\/mol.113.089755_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","article-title":"Metformin therapy in a transgenic mouse model of Huntington\u2019s disease","volume":"411","author":"Ma","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1124\/mol.113.089755_bib19","first-page":"43","article-title":"Valproic Acid related metabolic syndrome in patients with epilepsy","volume":"194","author":"Mania","year":"2011","journal-title":"Georgian Med News"},{"key":"10.1124\/mol.113.089755_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1124\/mol.113.089755_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"issue":"Suppl 1","key":"10.1124\/mol.113.089755_bib22","first-page":"S14","article-title":"Valproic acid and metabolites: pharmacological and toxicological studies","volume":"25","author":"Nau","year":"1984","journal-title":"Epilepsia"},{"key":"10.1124\/mol.113.089755_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0022-3565(25)32998-8","article-title":"Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse","volume":"220","author":"Nau","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.113.089755_bib24","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.089755_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-008-9916-5","article-title":"Therapeutic metformin\/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model","volume":"113","author":"Phoenix","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/mol.113.089755_bib26","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"key":"10.1124\/mol.113.089755_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1124\/mol.113.089755_bib28","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1111\/j.1460-9568.2004.03765.x","article-title":"Benefit of valproic acid in suppressing disease progression of ALS model mice","volume":"20","author":"Sugai","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1124\/mol.113.089755_bib29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1081\/CLT-120014645","article-title":"Valproic acid toxicity: overview and management","volume":"40","author":"Sztajnkrycer","year":"2002","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1124\/mol.113.089755_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/088307380201700405","article-title":"Insulin resistance in epileptic girls who gain weight after therapy with valproic acid","volume":"17","author":"Verrotti","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1124\/mol.113.089755_bib31","first-page":"E1","article-title":"AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes","volume":"277","author":"Winder","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1124\/mol.113.089755_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0887-8994(02)00505-2","article-title":"Valproic acid-associated weight gain in older children and teens with epilepsy","volume":"28","author":"Wirrell","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1124\/mol.113.089755_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.113.089755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:17:52Z","timestamp":1739963872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24038409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0026895X24038409"],"URL":"https:\/\/doi.org\/10.1124\/mol.113.089755","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.113.089755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}